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ABSTRACT

Objective:
The objective of this systematic review is to determine whether or not “Does N-acetylcysteine
supplementation alleviate compulsive behavior in adults with impulse control disorders?”
Study Design:
Review of three English primary studies published between 2007 and 2009.
Data Sources:
One double-blind RCT, one open label trial followed by double-blind RCT, one case study.
Studies were found using PubMed, Cochrane Systematic Reviews, OVID and Ebsco databases.
Outcomes Measured:
Primary outcomes measured include severity of trichotillomania symptoms measured by MGHHPS, reduction of pathological gambling symptoms measured by YBOCS-PG, and reduction of
compulsive grooming urges measured by patient reports.
Results:
In Grant, Odlaug et al.’s study, 44% of subjects assigned to NAC had a 50% or greater reduction
on the MGH-HPS compared to 0% of those assigned to placebo. In Grant, Kim et al.’s study,
69.6% of subjects were responders on the PG-YBOCS at the end of the open-label NAC phase.
At the end of the double-blind phase of the same trial, 83.3% of subjects assigned to NAC still
met responder criteria, compared to 28.6% of subjects assigned to placebo. In Odlaug et al.’s
study, 3 out of 5 subjects treated with NAC reported cessation of compulsive behaviors within 35 months on 1800-2400 mg/day NAC.
Conclusions:
Evidence is inconclusive regarding the use of NAC in the treatment of impulse control disorders.
Its use appears promising, but long term research in larger populations is indicated. Tailored
treatment may be warranted based on the severity and type of impulse control disorder, the
presence of co-morbid psychiatric disease, and individual treatment responses. Further insight
into long-term effects of NAC is indicated before its widespread use in the clinical setting.
Key Words:
N-acetylcysteine, trichotillomania, pathological gambling, glutamate, impulse control disorders
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Introduction
Impulse control disorders (ICD’s) are relatively common psychiatric disorders for which
the primary etiology is unknown.1 They are characterized by the irresistible impulse to engage in
behaviors that are harmful or destructive to oneself or others.2 The DSM-IV currently recognizes
the following ICD’s: pathological gambling (PG), kleptomania, trichotillomania (TTM),
intermittent explosive disorder, and pyromania. Pathological skin picking (PSP), compulsive
sexual behavior and compulsive buying are classified as Impulse Control Disorders Not
Otherwise Specified.2 Consequences of ICD’s include impaired social and occupational
functioning, decreased quality of life, financial loss and legal consequences.3, 4 This review is
limited to the discussion of PG, TTM, and pathological grooming disorders including PSP.
In the US, the estimated lifetime prevalence of PG and TTM is 0.4-1.6% and 0.5-3.9%,
respectively.2 Lifetime prevalence of PSP has been estimated to be 0.2-1.4% in the general
population,2 2% of dermatology patients, and 3.8% of college students.5 Costs incurred for PSP
and TTM include physicians’ and hospital fees, medication, psychotherapy, and cosmetic
products and procedures to hide scarring and bald spots.6 Total costs for PG including health care
expenses are estimated to be $5 billion annually.7 Estimated total health care costs and amount of
annual health care visits for ICD’s are not available at this time.
ICD’s are relatively common, yet their nature and treatment are poorly understood by
health care providers.3 At this time there are no FDA-approved drugs for treatment of ICD’s.2
Current methods of treatment include opioid antagonists, mood stabilizers, anti-depressants,8
cognitive behavioral therapy (CBT),2 and support groups such as Gamblers Anonymous1 or Hair
Pullers Anonymous. Individuals with TTM may benefit from topical steroids, hydroxyzine
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hydrochloride or hypnosis.1 Treatments being used are not effective for all patients and more
options are needed to optimize patient care.3, 4
Animal studies have led to the hypothesis that the pathophysiology of behavioral
addictions involves glutamate and dopamine actions in the nucleus accumbens.4 The reduction of
compulsive behavior has been associated with restoration of extracellular glutamate
concentration in the nucleus accumbens.3 N-acetylcysteine (NAC) is a hepatoprotective
antioxidant believed to increase extracellular glutamate levels.4 In animal models, NAC has
successfully penetrated the blood–brain barrier9 and reduced compulsive and reward-seeking
behavior in rats with cocaine addiction.4 The question of whether the glutamatergic modulator
NAC can have the same effect in humans has prompted various studies on the subject.
NAC has been used for decades in the treatment of paracetamol overdose and more
recently as a mucolytic and in the treatment of HIV.9 NAC has also shown some benefit in
treating COPD and contrast-induced nephropathy.9 NAC may be effective as a relatively cheap
non-prescription treatment for individuals with ICD’s. Treatment with NAC may be relevant to
psychiatry based on its mechanism of action in non-specific pathways common to various
psychopathologies.9 Alterations of oxidative stress, dysregulation of glutamate, and
inflammatory pathways have been elucidated in psychiatric disease.9 NAC’s potential effect on
these pathways makes it a source of continued interest. Furthermore, NAC’s limited adverse
event profile may make it a good alternative to other pharmaceutical agents.4 This paper attempts
to determine the efficacy of NAC as a treatment option for individuals with ICD’s.
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Objective
The objective of this systematic review is to determine whether or not “Does Nacetylcysteine supplementation alleviate compulsive behavior in adults with impulse control
disorders?”
Methods
Studies reviewed include one case study, one double-blind RCT, and one open label trial
followed by a double-blind RCT. All three studies analyze the effects of N-acetylcysteine in
individuals over the age of 18 with a DSM-IV diagnosis of an impulse control disorder.3,4,5
The intervention applied in each study is NAC in doses between 600-2400 mg/day.3,4,5
Subjects of the Grant, Kim et al. and Grant, Odlaug et al. studies were compared to an
experimental group receiving an identical placebo for 12 weeks and 6 weeks, respectively.3,4
Results from these two studies were obtained from clinical questionnaires. 3,4 Subjects in the
Odlaug et al. study were not evaluated against a comparison group and results were obtained
from patient reports. 5 Subjects in the Odlaug et al. study were treated for several months.5
The author searched for articles using PubMed, Cochrane Systematic Reviews, OVID
and Ebsco using the keywords “N-acetylcysteine,” “trichotillomania,” “pathological gambling,”
“glutamate,” and “impulse control disorders.”All articles were published in English in peerreviewed journals. The inclusion criteria were RCT’s or case studies published after 1996 of
adults aged 18 or older with an ICD. Articles were selected based on validity of the clinical
trials, relevance to the author’s clinical hypothesis, and the inclusion of POEM’s. Studies of
individuals under the age of 18 were excluded. Grant, Odlaug et al.’s study included CER, EER,
a p-value of <.001 and a 95% confidence interval(CI).3 Grant, Kim et al.’s study included CER,
EER, and a p-value of <.001.4 Studies were further evaluated by the author for RRR, ARR, and
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NNT. Odlaug et al.’s study did not include statistical values. Table 1 provides demographic
information and specific characteristics of the studies included in this review.
Table 1: Demographics and Characteristics of Included Studies
Study

Type

#Pts Age Inclusion Criteria
Exclusion Criteria
W/D Interventions
(yrs.)
Grant, Double- 50 18-59 Men and women
History of seizures, unstable 6
NAC 1200 mg/day
Odlaug blind
aged 18-65 with a
medical illness, bipolar
x6 wks increased
et al.
RCT
primary DSM-IV
disease, dementia,
to 2400 mg/d for
(2009)
diagnosis of
schizophrenia or psychotic
remaining 6 weeks
trichotillomania.
disorder; abnormalities on
unless clinical
Women required a physical exam/lab tests at
improvement
negative pregnancy screening; MI within 6 mos.,
occurred at lower
test result and the use substance abuse/dependence
dose
of a medically
within 3 mos.; Current
acceptable
pregnancy/lactation; Lack of
contraceptive
contraception in women of
throughout the study childbearing age; Reported
suicidal thoughts; Previous
NAC treatment; Asthma
Grant, Open
27 21- Men and women
Gambling not meeting DSM- 4
NAC 600 mg/d x2
Kim et Label
65 aged 18-75 with a
IV criteria for PG; Current
wks, increased to
al.(2007) Trial
primary DSM-IV
1200 mg/day x2
pregnancy/lactation; Lack of
diagnosis of PG;
wks, increased
contraception in women of
to1800 mg/d for
Score of 15 or
childbearing age; History of
remainder of study
greater on PGseizures, unstable medical
unless clinical
YBOCS; Subjects
illness, bipolar disease,
improvement
required to have
dementia, schizophrenia,
occurred at lower
gambled within a
psychotic disorder;
dose
week prior to
abnormalities on physical
enrollment ;Women exam at screening; MI within 6
Subjects who
required a negative mos., substance
responded to openpregnancy test result abuse/dependence within 3
label NAC
and the use of
mos.; Previous NAC
randomized to dose
medically acceptable treatment; Positive urine drug
at which they
Followed 16
3
contraceptive
screen test; psychotherapy or
completed openby
throughout the study behavior therapy initiated
label phase or
Doublewithin 3 mos. of study
identical placebo
Blind
RCT
Odlaug Case
5
28-52 Adults with
N/A
2
N-acetylcysteine
et
Study
pathological
600-2400 mg/d
al.(2007)
grooming behaviors
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Outcomes Measured
Outcomes measured include the efficacy and tolerability of NAC in adults with TTM
and in adults with PG, severity of TTM symptoms, reduction of PG symptoms, reduction of
compulsive grooming behaviors, reduction of anxiety and depression, psychosocial function, and
quality of life.3,4,5 Each of these outcomes qualifies as patient oriented evidence that matters.
The primary outcome measured in Grant, Odlaug et al.’s study was severity of TTM
symptoms, measured by the Massachusetts General Hospital Hair Pulling Scale (MGH-HPS).3
This is a 7-item scale that rates hair pulling urges and the associated behaviors and emotions.3
Total scores range from 0-28.3 Secondary outcome measures in this study were measured by the
Psychiatric Institute Trichotillomania Scale (PITS), Hamilton Anxiety Rating Scale (HAM-A),
Hamilton Depression Rating Scale (HAM-D), Sheehan Disability Scale (SDS), Clinical Global
Impression-Improvement and Severity Scales (CGI), and Quality of Life Inventory (QOLI).3
This review is limited to results from MGH-HPS.
The primary outcome measured for the subjects of the Grant, Kim et al. study was
reduction of PG symptoms, measured by The Yale Brown Obsessive Compulsive Scale
Modified for Pathological Gambling (PG-YBOCS).4 This is a reliable 10-item clinicianadministered scale rating gambling symptoms from the past 7 days. 4 Total scores range from 040.4 Secondary measures were assessed using the Gambling Symptom Assessment Scale (GSAS), CGI, SDS, HAM-A, HAM-D, and QOLI.4 This review is limited to results from the PGYBOCS.
The primary outcomes measured in Odlaug et al. were the reduction of compulsive
grooming behaviors and associated urges.5 Specific behaviors included nail biting, hair pulling
and skin picking, measured by reports from subjects.5
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Results:
Table 2: Key Values from Trials Being Reviewed in This Paper
P value

CER

EER

RRR

ARR

NNT

Grant, Odlaug et al. (2009)

<.001

0

44%

undefined

0.44

2 patients

Grant, Kim et al. (2007)

<.001

28.6%

83.3%

1.9

0.547

2 patients

Oudlaug et al. (2007)

N/A

N/A

N/A

N/A

N/A

N/A

The Grant, Odlaug et al. study involved a 12-week double-blind, placebo-controlled trial.
Fifty subjects with trichotillomania were randomized to 12 weeks of double-blind NAC or
placebo. Results were presented as dichotomous data analyzed with the last observation carried
forward in the intention-to-treat (ITT) population. Primary and secondary measures were
examined using ANOVA. Twenty two out of 25 subjects (88%) assigned to NAC and 22 out of
25 subjects (88%) assigned to placebo completed the trial. Those who did not were either noncompliant with the medication or could not complete the study due to unrelated health reasons.3
Subjects were seen every 3 weeks for 12 weeks. For the first 6 weeks subjects were given
1200 mg/day NAC or identical placebo. NAC or placebo was increased to 2400 mg/day for the
remaining 6 weeks unless clinical improvement occurred at a lower dose. MGH-HPS total scores
decreased from a mean of 17.6 ± 4.64 at baseline to 10.4 ± 5.55 (95% CI and p<.001.)3 (Table 3)
Table 3: Results of Double-blind NAC/Placebo Therapy in 50 TTM Subjects
Variable

MGH-HPS
Total Score
a

Baseline Placebo
Group (n=25)
16.7 (5.28)a

Baseline NAC
Group (n=25)
17.6 (4.64)a

End Point
Placebo Group
(n=25)

End Point NAC
Group (n=25)

P value

16.0 (4.90)a

10.4 (5.55)a

<.001

CI

95%

Value, mean (SD)

Of the 25 subjects assigned to NAC, 44% (n=11) had a 50% or greater reduction on the
MGH-HPS compared to 0% of those assigned to placebo (95% CI, p<.001). 3 NAC therapy in
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TTM subjects demonstrates an experimental event rate (EER) of 44% and a control event rate
(CER) of 0. The absolute risk reduction (ARR) is calculated at 44% and the number needed to
treat (NNT) a TTM patient effectively with NAC is 2. (Table 2)
Demographic features including but not limited to age, gender, age at TTM onset, and
TTM severity did not cause statistically significant differences in treatment response among
subjects.3
Evaluations of blood pressure, heart rate and weight were recorded at each visit. Adverse
effects included nausea, diarrhea and cough, experienced only in the placebo group.3 (Table 4)
Table 4: Patients with TTM Reporting Adverse Effects
Adverse Drug Event

Placebo Group (n=25)

NAC Group (n=25)

P value

Nausea

1 (4%)

0

>.99

Diarrhea

2 (8%)

0

0.49

Cough

1(4%)

0

>.99

In the Grant, Kim et al. study, 27 pathological gambling subjects were included in the ITT
analysis. Of these, 23 (85.2%) were able to keep to the study schedule and complete the study.
Data were presented as dichotomous and were analyzed with the last observation carried forward
in the ITT population. The study included an open-label trial followed by a double-blind RCT.4
In the 8-week open-label component, PG subjects were seen weekly for weeks 1-4, then
biweekly for weeks 4-8. Subjects were started on 600 mg/day of unblinded NAC for 2 weeks.
NAC was increased to 1200 mg/day for the next 2 weeks, then to 1800 mg/day for the remainder
of the study. Doses were not increased if clinical improvement was observed at a lower dose.4
PG-YBOCS scores decreased from a mean of 20.3 ± 4.08 at baseline to 11.8 ± 9.81 after 8
weeks [t(50)= 4.17 and p<.001].(Table 5) Responders were defined as those with a ≥30%
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decrease in PG-YBOCS total score. Considering only those who completed the study, (n=23) ,16
(69.6%) were responders on the PG-YBOCS at the end of the open-label phase.4
Table 5: Results of Open-Label N-Acetylcysteine Treatment in 27 PG Subjects
Measure
PG-YBOCS Total
a

Baseline
20.3 ± 4.08a

Week 8 End Point
11.8± 9.81a

Paired t test

p

4.17

<.001

Value, mean (SD)

Of the 16 subjects who responded to NAC, 13 continued with the 6-week double-blind
phase. Three subjects chose not to assume the risk of loss of improvement in gambling
symptoms. Six of the 13 subjects were randomized to the NAC dose at which they completed the
open-label phase and 7 were randomized to an identical amount of placebo. At the end of the
double-blind phase, 5 out of 6 subjects (83.3%) assigned to NAC still met responder criteria,
compared to 2 out of 7 subjects (28.6%) assigned to placebo.(Figure 1) NAC also maintained
improvement on the primary outcome measure, the PG-YBOCS Total Score (Table 6). 4
“Figure 1. Percentage of subjects meeting responder criteria each week of the double-blind
discontinuation phase. a”

a

This figure and its title comes directly from Grant, Kim et al.4

Table 6: Results of 13 PG Subjects Randomized to NAC or Placebo for 6 Weeks
Outcome Measure

Mean Rank

Z Score

p

PG-YBOCS Total Score
Placebo

10.6

Active

7.2

-1.67

0.095
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NAC supplementation in individuals with PG demonstrates an EER of 83.3% and a CER
of 28.6%.4 This study demonstrates a RRR of 190% and an ARR of 54.7% for pathological
gamblers taking NAC. The number needed to treat (NNT) a pathological gambler with NAC
based on these results is two (Table 2). The mean effective daily dose of NAC was 1476.9 ±
311.3 mg. The only adverse event was mild flatulence, reported by two subjects.4
In the case study by Odlaug et al., five subjects were enrolled and underwent structured
clinical interviews. 5 Two of the five subjects (40%) did not respond to treatment with NAC. 5
Results of this study include those of the three individuals who responded.
The first subject reported cessation of urges to engage in nail biting and hair pulling for 3
months on1800 mg/day of NAC. The only side effect reported was mild flatulence during the
first 2 weeks. The second subject achieved abstinence from TTM symptoms after 5 months of
2400 mg/day NAC. She reported the cessation of hair pulling and associated urges and was able
to stop wearing her wig. She reported no side effects. The third subject reported 4 months of
abstinence from skin picking with only occasional mild urges on 1800 mg/day. Reports of her
side effects were not included in the study. 5 (Table 7)
Table 7: Results of NAC in Individuals with Pathological Grooming Disorders
Subject

Diagnosis

Symptoms

28 y.o.
white male

Nail biting x
22 yrs and
TTM x16 yrs

Daily biting 2-3
hrs/d; Hair pulling
30 min/d;
Significant social
impairment

40 y.o.
white
female

TTM x 36
years

Daily hair pulling
from head and pubic
area; intense shame
+ embarrassment

Intervention

Result

Adverse
effects

NAC 600 mg/d x 2
wks increased to
1200 mg/d, then to
1800 mg/d

Cessation of
urges/thoughts to
engage in compulsive
behavior x 3 mos.

Mild
flatulence
x 2 weeks

NAC 600 mg/d
increased to 1200
mg/d, then to 1800
mg/d, finally to 2400
mg/d

Cessation of pulling +
urges; Ability to stop
wearing wig;
Abstinence at 5 mos.

None
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Subject

Diagnosis

Symptoms

52 y.o.
African
American
female

Skin picking
x 37 years

Daily uncontrollable
picking of skin on
arms + legs;
Frequent infections

Intervention
NAC 600 mg/d
increased to 1200
mg/d, then to 1800
mg/d

Result
Absence of picking
behavior w/ only
occasional mild urges
x 4 mos.

Adverse
effects
Not
reported

Discussion:
Grant, Odlaug et al.’s study shows improvement on the primary outcome measure in the
experimental group with effects seen within 9 weeks of treatment initiation.3
Grant, Kim et al.’s study shows improvement of PG symptoms in the majority of subjects
taking NAC. This study, however, has some limitations. Findings were based on a small
population and only NAC responders were included in the second trial phase, possibly leading to
exaggeration of NAC’s effects relative to placebo. 4Also, subjects with depression were taking
medications in addition to the NAC, possibly affecting its efficacy. 4 An interesting finding in
this study was that the few subjects taking psychotropic medications did not respond to NAC. 4
Odlaug et al.’s study, while informative, consisted of a particularly small population size
and only studied those who saw improvement with NAC. Controlled studies to investigate the
same interventions applied in this study are needed to confirm the findings.
The above trials were limited by the fact that the optimal effective dose of NAC has yet
to be established.9 Subjects in the above trials who did not respond to NAC or who responded
minimally may have had better outcomes with higher doses. Overdose of NAC, however, can
lead to seizures and vigilance with its administration necessary 9. Secondly, the long-term effects
of NAC can not be assessed from these studies, which designed brief treatment periods in a
population of subjects with a chronic, often lifelong disorder.4 Longer term treatment may have
shown higher levels of response. Lastly, these studies did not examine NAC treatment in
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conjunction with CBT, which has proven to be beneficial in the treatment of ICD’s.3 The
potential synergistic effects of CBT with NAC supplementation has yet to be investigated.
Conclusion:
The studies reviewed provide inconclusive evidence regarding the use of NAC in the
treatment of impulse control disorders. NAC appears to be a promising alternative, but given the
small population sizes and short-term use in the studies reviewed, further research is required.
ICD’s may require more individualized treatment approaches based on the severity and type of
ICD, presence of co-morbid psychiatric disease, and individual treatment response. Future
studies focused on NAC treatment in conjunction with other treatments and in tailored amounts
would provide more insight. NAC is generally well-tolerated with minimal adverse effects, but
there is currently no evidence for adverse outcomes with long-term use. 9 Long-term effects must
be understood before NAC can be used in the clinical setting.
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